Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04271644 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

StatusRecruiting
PhasePhase 1/2
Started2019-04-01
View on ClinicalTrials.gov ↗

Amendment history

2025-02-23
Study Identification, Study Status, Eligibility, IPDSharing v3
Primary completion date2023-12-31→2026-12-31
Completion date2024-07-01→2027-07-01
Eligibility criteria+29 characters
Inclusion Criteria: Signed written informed consent; Diagnose as relapsed /refractory multiple myeloma or other plasma cell disease, and meet one of the following conditions: Failed to standa [...]
Study title+24 characters
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
2023-04-16
Study Status v2
Primary completion date2022-12-30→2023-12-31
Completion date2023-07-01→2024-07-01
2021-03-01
Study Identification, Study Status v1
Re-verified, no change to tracked fields
2020-02-14
Original filing
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Trial Details
NCT Number NCT04271644
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
Enrollment 80 participants
Start Date 2019-04-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-25